Sort
10,766 grants matching “checkpoint inhibitor”
Analyzing genetic and environmental molecular mechanisms causing autoimmune thyroid diseases
$403,200Yaron Tomer · Albert Einstein College Of Medicine · R01 · FY2024 · DK
Pro-tumor functions of neutrophils in squamous cell lung cancer
$403,102Trudy Gale Oliver · Duke University · R01 · FY2023 · CA
Fatty Acid Synthase as a Novel Molecular Target for Colon Cancer Treatment
$402,968Tianyan Gao · University Of Kentucky · R01 · FY2024 · CA
Fatty Acid Synthase as a Novel Molecular Target for Colon Cancer Treatment
$402,968Tianyan Gao · University Of Kentucky · R01 · FY2025 · CA
Project 1: Targeting immunotherapy-induced resistance with DC vaccination and PD-1/CSF-1R inhibition
$402,824Robert M Prins · University Of California Los Angeles · P50 · FY2025 · CA
Targeting Lag-3 and PD -1 in Myeloid Cells of GBM
$402,791Michael Lim · Stanford University · R01 · FY2022 · NS
Defining the impact of intra-tumoral morphologic, immune and mutational heterogeneity in urothelial carcinoma
$402,618Hikmat Al-Ahmadie · Sloan-Kettering Inst Can Research · R01 · FY2022 · CA
Defining the impact of intra-tumoral morphologic, immune and mutational heterogeneity in urothelial carcinoma
$402,618Hikmat Al-Ahmadie · Sloan-Kettering Inst Can Research · R01 · FY2023 · CA
Neoadjuvant Tucatinib plus Trastuzumab in HER2-amplified Locally Advanced Rectal Cancer
$402,600Andrea Cercek · Sloan-Kettering Inst Can Research · R01 · FY2024 · CA
Neoadjuvant Tucatinib plus Trastuzumab in HER2-amplified Locally Advanced Rectal Cancer
$402,600Andrea Cercek · Sloan-Kettering Inst Can Research · R01 · FY2025 · CA
Mechanism and therapeutic potential of microglia regulation in glioblastoma
$402,500Peiwen Chen · Cleveland Clinic Lerner Com-Cwru · R01 · FY2025 · NS
Cooperation of SF3B1 mutations and ATM deletions in the pathogenesis of chronic lymphocytic leukemia
$402,484Lili Wang · Beckman Research Institute/City Of Hope · R01 · FY2024 · CA
Discovery of New Treatment Options for EBV-associated Lymphoma and PTLD
$402,448Richard M Longnecker · Northwestern University At Chicago · R01 · FY2011 · CA
In situ radioimmunotherapy to maximize the engagement of conventional type 1 dendritic cells against non-T cell-inflamed tumors
$402,417Fumito Ito · University Of Southern California · R01 · FY2022 · CA
Antitumor potential of AvFc lectibody in non-small cell lung cancer
$402,402Nobuyuki Matoba · University Of Louisville · R21 · FY2023 · CA
Targeting CXCR2+ PMN-MDSCs for immunotherapy of hepatoblastoma
$402,400Xin Chen · University Of Hawaii At Manoa · R21 · FY2025 · CA
Epigenetic Reprogramming of T cell Exhaustion To Enhance Tumor Immunotherapy
$402,394Benjamin Alan Youngblood · St. Jude Children'S Research Hospital · R01 · FY2022 · CA
Epigenetic Reprogramming of T cell Exhaustion To Enhance Tumor Immunotherapy
$402,394Benjamin Alan Youngblood · St. Jude Children'S Research Hospital · R01 · FY2023 · CA
A prognostic mRNA immune signature for resected stage II-III melanoma
$402,257Yvonne Margaret Saenger · Albert Einstein College Of Medicine · UH3 · FY2022 · CA
Evaluation of Immune-based Combinations in Metastatic Prostate Cancer
$402,223Ravi Madan · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Covalent Protein Binders for Cancer Research and Therapy
$402,207Lei Wang · University Of California, San Francisco · R01 · FY2021 · CA
Project 4 :Using TME genetics and immunobiology to drive combination immunotherapies
$402,156Elizabeth Marion Jaffee · Johns Hopkins University · P50 · FY2021 · CA
Viral mechanism for engaging lytic cycle promoting host transcription factors
$402,150Bernadett Papp · University Of Florida · R21 · FY2025 · AI
Salmonella as a vector for delivery of oncolytic viruses to hepatocellular carcinoma
$402,147Neil S Forbes · University Of Massachusetts Amherst · R21 · FY2024 · CA
Linking Epigenetic-Therapy Induction of Inflammasome Signaling to Generation of a BRCAness Phenotype
$401,744Kenneth P Nephew · Coriell Institute For Medical Research · P50 · FY2024 · CA